Table 2. Comparison of diagnostic... | American Society of Hematology

Table 2.

Comparison of diagnostic characteristics and OS rates

Characteristics	Group 1 OS, %	Group 2 OS, %	P	Group 2A OS, %	Group 2B OS, %	P
Age, y
0-5	64	45	.11	58	26	.12
6-10	46	54	.85	50	57	.96
11-18	54	78	.20	79	77	.89
Central nervous system disease
No	55	54	.66	59	49	.45
Yes	83	67	.52	62.5	100	.51
French-American-British
M0	100	100	—	100	—	—
M1	58	60	.87	56	67	.46
M2	48	46	.87	56	41	.54
M3	75	72	.96	82	67	.79
M4	32	68	.19	61	80	.31
M4Eo	80	0	.02^*	—	0	—
M5	61	42	.35	52	23	.02
M6	0	0	—	0	—	—
M7	100	71	.34	71	—	—
Granulocytic sarcoma	—	100	—	100	100	—
Unclassifiable	100	33	.36	33	—	—
Cytogenetics
Good	78	69	.17	74	65	.97
Standard	44	49	.47	55	44	.46
Poor	50	42	.51	38	50	.60
No result	70	59	.45	78	25	.14

Characteristics	Group 1 OS, %	Group 2 OS, %	P	Group 2A OS, %	Group 2B OS, %	P
Age, y
0-5	64	45	.11	58	26	.12
6-10	46	54	.85	50	57	.96
11-18	54	78	.20	79	77	.89
Central nervous system disease
No	55	54	.66	59	49	.45
Yes	83	67	.52	62.5	100	.51
French-American-British
M0	100	100	—	100	—	—
M1	58	60	.87	56	67	.46
M2	48	46	.87	56	41	.54
M3	75	72	.96	82	67	.79
M4	32	68	.19	61	80	.31
M4Eo	80	0	.02^*	—	0	—
M5	61	42	.35	52	23	.02
M6	0	0	—	0	—	—
M7	100	71	.34	71	—	—
Granulocytic sarcoma	—	100	—	100	100	—
Unclassifiable	100	33	.36	33	—	—
Cytogenetics
Good	78	69	.17	74	65	.97
Standard	44	49	.47	55	44	.46
Poor	50	42	.51	38	50	.60
No result	70	59	.45	78	25	.14

Group 1, daunorubicin; group 2, idarubicin; group 2A, 10 mg/m² idarubicin; group 2B, 12 mg/m²idarubicin.

P < .05.